CF
AARD

Cantor Fitzgerald’s Aardvark Therapeutics AARD Stock Holding History

Cantor Fitzgerald’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Sell
66,682
-25,000
-27% -$259K ﹤0.01% 251
2025
Q4 		$1.2M Sell
91,682
-5,000
-5% -$62.4K 0.02% 153
2025
Q3 		$1.28M Buy
96,682
+20,000
+26% +$226K 0.01% 194
2025
Q2 		$1.04M Buy
76,682
+10,000
+15% +$103K 0.02% 154
2025
Q1 		$501K Buy
+66,682
New +$749K 0.01% 154

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cantor Fitzgerald's AARD Position: Q1 2026 in Review

Cantor Fitzgerald reduced its Aardvark Therapeutics (AARD) stake by 27% in Q1 2026, selling an estimated $259K and leaving 66,682 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #251.

Cantor Fitzgerald first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.28M in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Cantor Fitzgerald held 66,682 shares of Aardvark Therapeutics worth $251K as of Q1 2026.
  • Cantor Fitzgerald sold 25,000 Aardvark Therapeutics shares in Q1 2026, an estimated $259K.
  • Aardvark Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #251 holding.
  • Cantor Fitzgerald first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Cantor Fitzgerald's Aardvark Therapeutics position peaked at $1.28M in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.